Clinical Trial Search

Primary: Percentage of Infant Participants With Medically Attended Lower Respiratory Tract Illness (MA-LRTI) Cases Due to RSV Occurring Within 90 Days After Birth (Efficacy)…

Primary: Number of Subjects With Any Solicited Local Adverse Events (AEs) During a 7-day Follow-up Period After the First Vaccination (Administered at Day 1) — 5; 6; 0; 22…

Primary: Geometric Mean Fold Rise Against RSV Fa Protein — 12.5; 9.9 fold change — p=0.14

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade (RSV-seropositive Participants) — 10; 9; 4; 0 Participants

Primary: Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI) — 8; 30; 10 percentage of participants

Primary: Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination With RSVpreF or Placebo — 10.1; 6.5; 7.6; 11.5 Percentage of participants

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade - (RSV-seropositive Participants) — 8; 5; 0; 0 Participants

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 21; 22; 11; 1 Participants

Primary: Number of Hospital Admissions by Respiratory Syncytial Virus Infection — 2 participants

Primary: Frequency of Adverse Events — 41 participants

Primary: SSA: Percentage of Participants With Local Reactions Within 7 Days After Vaccination — 29.7; 10.2; 5.5; 0.4 Percentage of Participants

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 17; 9; 3; 1 Participants

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 16; 10; 0; 0 Participants

Primary: Number of Participants With Adverse Events — 99 Participants

Primary: Infants: Percentages of Participants With Medically Significant RSV LRTI With Either Hypoxemia (SpO2 <95% at Sea Level or <92% at Altitudes >1800 Meters) or Tachypnea…

Primary: Geometric Mean Titer (GMT) of Serum Neutralizing Titers (NTs) for Respiratory Syncytial Virus Subgroup A (RSV A) and Respiratory Syncytial Virus Subgroup B (RSV B)…

Primary: RSV-A Serum Neutralizing Titers Expressed As Mean Geometric Increase (MGI) Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group — 1.34 Ratio

Primary: Frequency of Grade 1 or Higher Solicited Adverse Events (AEs) by Grade — 14; 7; 27; 11 Participants

Primary: Circulating RI-001 Titer — 9.24; 4.85; 1.42 Fold Change

Primary: Area Under the Viral Load-time Curve (VL-AUC) of RSV — 0.00; 96.65 h*log10 PFU/mL

Primary: RSV-A Neutralization Antibody Titers Expressed as Geometric Mean Titers (GMTs) — 10060.5; 12255 Titers (ED 60)

Primary: Number of Subjects With Required Adverse Events Grade II, III, and IV, Laboratory Adverse Events Grade II, III, and IV, and Severe Considered Adverse Events Related to…

Primary: Part A: RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs) — 11910.1; 8593.6 Titer

Primary: Percentage of Maternal Participants With Prespecified Local Reactions by Maximum Severity Within 7 Days After Vaccination — 3.5; 2.6; 5.2; 0.9 Percentage of participants

Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination — 36.0; 39.1; 8.3; 35.3 Percentage of participants

Primary: Sentinel Cohort: Percentage of Participants (Aged 18 to 49 Years) With Local Reactions Within 14 Days After Vaccination — 50.0; 58.3; 25.0; 75.0 Percentage of participants

Primary: Number of Subjects With Any Solicited Local Adverse Events (AEs) — 1; 2; 0; 2 Participants

Primary: RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs) — 5876.3; 6935.3 Titers

Primary: Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose of Vaccination — 1; 0; 17; 1 Participants

Primary: Percentage of Maternal Subjects With Any Solicited Administration Site Events — 57.1; 52; 15.2; 1.4 Percentage of maternal subjects